產(chǎn)地 | Rubicon |
品牌 | Rubicon |
貨號 | RB3050/R30050 |
保存條件 | -20度 |
英文名稱 | Rubicon Genomics (RB3050/R30050) PicoPLEX® WGA Kit |
保質(zhì)期 | 1年個月 |
產(chǎn)品中文名稱:Rubicon Genomics (RB3050/R30050)單細胞全基因組擴增試劑盒
產(chǎn)品英文名稱:Rubicon Genomics (RB3050/R30050) PicoPLEX® WGA Kit
華雅思創(chuàng)生物目前倉庫現(xiàn)貨
微量DNA的金鑰匙:單細胞全基因組擴增試劑盒 僅需2小時三步法精準(zhǔn)可靠 Rubicon Genomics (RB3050/R30050) PicoPLEX® WGA Kit
Whole Genome Amplification from Single Cells
Rubicon Genomics成立于2000年,總部位于美國密歇根州。該公司的核心競爭力產(chǎn)品包括酶學(xué)、核酸化學(xué)、樣品的加工生產(chǎn),該公司致力于創(chuàng)新、知識產(chǎn)權(quán)的發(fā)展和持續(xù)的產(chǎn)品開發(fā)。
Rubicon Genomics開發(fā)創(chuàng)新、高品質(zhì)的、核酸文庫的制備及配套產(chǎn)品,能夠?qū)εR床樣本進行簡單、快速可靠和高靈敏度的分析。
美國Rubicon Genomics---單細胞測序文庫構(gòu)建的領(lǐng)導(dǎo)品牌Rubicon Genomics (RB3050/R30050)單細胞全基因組擴增試劑盒
1. 二代測序建庫試劑(微量起始樣品 50pg - 50ng)
2. 單細胞擴增和單細胞測序建庫試劑(廣泛應(yīng)用于生殖領(lǐng)域,是該領(lǐng)域的金標(biāo)準(zhǔn)。)
3. 全RNA擴增試劑(微量起始樣品,可以低至10個細胞的總RNA)
Rubicon Genomics (RB3050/R30050) PicoPLEX® WGA Kit 單細胞全基因組擴增試劑盒
Rubicon Genomics (RB3050/R30050)單細胞全基因組擴增試劑盒是應(yīng)用于一般用途的Illumina下一代測序(NGS)的高性能文庫,ThruPLEX的DNA測序試劑盒具有較低的和更廣泛的輸入范圍。PicoPLEX®
WGA Kit 單細胞全基因組擴增試劑盒具有較低的和更廣泛推薦的輸入范圍比其他工具包。對于Rubicon Genomics
的PicoPLEX® WGA Kit
單細胞全基因組擴增試劑盒樣品輸入量為20倍,比其他套件更為敏感,從第50和50納克,不需要協(xié)議或適配器濃度的優(yōu)化。索引和適配器附帶套件。
PicoPLEX® WGA Kit高性能的*輸入:50 PG 50納克
PicoPLEX® WGA Kit完整的包,用于創(chuàng)建庫:優(yōu)化索引和適配器試劑,酶,緩沖劑,和無核酸酶水
PicoPLEX® WGA Kit 其操作僅在一個管3步驟和僅約2小時,沒有必要調(diào)劑
【產(chǎn)品性能】
Rubicon Genomics (RB3050/R30050) PicoPLEX® WGA Kit 單細胞全基因組擴增試劑盒
Amplification of Single Cells is Reproducible
Flow-sorted cancer cells were amplified with the PicoPLEX WGA Kit. Each
of the cells (blue lines) amplified at the same rate, and resulted in a
similar, predictable yield. The sample containing 0 cells (green lines;
no template control) shows very low background.
擴增單個細胞是可重復(fù)的
流分類的癌細胞用PicoPLEX® WGA Kit 單細胞全基因組擴增試劑盒擴增。每個細胞(藍線)以相同的速率擴增,并導(dǎo)致類似的,可預(yù)測的產(chǎn)率。包含0個單元格(綠線,沒有模板控制)的樣本顯示非常低的背景。
Rubicon Genomics (RB3050/R30050)單細胞全基因組擴增試劑盒參考文獻如下:
Cell-free DNA
?Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer.
?Xia et al. Oncotarget, 2016 Apr 26. doi: 10.18632/oncotarget.9027.
?Evaluation of exome sequencing to estimate tumor burden in plasma
?Klevebring et al. PLos One. 2014 Aug 18;9(8): e104417. DOI: 10.1371/journal.pone.0104417. eCollection 2014.
?Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
?Murtaza et al. Nature. 2013 May 2;497(7447):108-12. DOI: 10.1038/nature12065.
?Epub 2013 Apr 7.
?Non-invasive whole-genome sequencing of a human fetus
?Kitzman et al. Sci Transl Med. 2012 Jun 6;4(137):137ra76. DOI: 10.1126/scitranslmed.3004323.
ChIP-seq
?Epigenomic profiling of young and aged HSCs reveals concerted changes during aging that reinforce self-renewal
?Sun et al. Cell Stem Cell. 2014 May 1;14(5):673-88. DOI: 10.1016/j.stem.2014.03.002.
?Large conserved domains of low DNA methylation maintained by Dnmt3a
?Jeong et al. Nat Genet. 2014 Jan;46(1):17-23. DOI: 10.1038/ng.2836.
?Bivalent chromatin marks developmental regulatory genes in the mouse embryonic germline in vivo
?Sachs et al. Cell Rep. 2013 May 30. pii: S2211-1247(13)00214-3. DOI:
?10.1016/j.celrep.2013.04.032.